Article
Immunology
Marta Santos Bravo, Nicolas Plault, Sonsoles Sanchez Palomino, Maria Mar Mosquera Gutierrez, Francesc Fernandez Aviles, Maria Suarez Lledo, Nuria Sabe Fernandez, Montserrat Rovira, Sophie Alain, M. Angeles Marcos Maeso
Summary: For transplant recipients with CMV infection resistant to standard therapy, MBV could be an effective treatment option. However, the emergence of MBV resistance should be carefully monitored through clinical follow-up and genotypic and phenotypic studies.
JOURNAL OF INFECTIOUS DISEASES
(2021)
Article
Pharmacology & Pharmacy
Sunwen Chou, Steven Kleiboeker
Summary: Genotypic testing for letermovir resistance revealed multiple sequence variants, with codon 325 mutations being the most common and capable of causing high-level resistance. Additionally, new mutations were identified, some of which conferred a 2-to 5-fold increase in the drug's inhibitory concentrations. These findings highlight the ongoing concern of the emergence of absolute letermovir resistance during therapy.
ANTIVIRAL RESEARCH
(2022)
Article
Medicine, General & Internal
Mina Tasoujlu, Davod Khalafkhany, Khadijeh Makhdoomi, Morteza Motazakker
Summary: This study detected UL97 gene mutations associated with ganciclovir resistance in kidney transplant recipients, and identified two mutations related to resistance. Furthermore, a higher mutation rate of D605E was observed in the recipients.
BRATISLAVA MEDICAL JOURNAL-BRATISLAVSKE LEKARSKE LISTY
(2022)
Article
Immunology
Sunwen Chou, Kening Song, Jingyang Wu, Tien Bo, Clyde Crumpacker
Summary: The study identified UL97 mutations T409M, H411Y, or C480F as conferring maribavir resistance in patients receiving maribavir therapy. The newly phenotyped mutation C480F showed high-grade maribavir resistance and low-grade ganciclovir resistance, posing challenges to treatment.
JOURNAL OF INFECTIOUS DISEASES
(2022)
Article
Medicine, General & Internal
Ajit P. Limaye, Klemens Budde, Atul Humar, Flavio Vincenti, Dirk R. J. Kuypers, Robert P. Carroll, Nicole Stauffer, Yoshihiko Murata, Julie M. Strizki, Valerie L. Teal, Christopher L. Gilbert, Barbara A. Haber
Summary: This study compared the efficacy and safety of letermovir with valganciclovir in preventing cytomegalovirus (CMV) disease in kidney transplant recipients. Results showed that letermovir was as effective as valganciclovir in preventing CMV disease over 52 weeks, with lower rates of leukopenia or neutropenia, supporting its use for this indication.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
(2023)
Article
Pharmacology & Pharmacy
Samuel D. Chorlton, Gordon Ritchie, Tanya Lawson, Elizabeth McLachlan, Marc G. Romney, Nancy Matic, Christopher F. Lowe
Summary: A next-generation sequencing (NGS) assay was developed for CMV antiviral drug resistance (AVDR) testing, which using MinION technology detected additional mutations compared to traditional Sanger sequencing. Through the application of an online bioinformatics pipeline, barriers associated with MinION and NGS in clinical laboratories were eliminated.
ANTIVIRAL RESEARCH
(2021)
Article
Virology
Vanessa Recio, Irene Gonzalez, David Tarrago
Summary: In a nationwide study, 26.87% of CMV positive transplant recipients had ARMs in UL97 and 10.60% had ARMs in UL54. The most prevalent ARMs were L595S/W and F412C, which conferred resistance to GCV and CDV. There was no significant difference in CMV load between patients with and without ARMs.
Article
Microbiology
Rabia Can Sarinoglu, Dilek Colak, Osman Alphan Kupesiz, Mert Ahmet Kuskucu, Koray Yalcin, Imran Saglik, Derya Mutlu, Kenan Midilli, Bilal Olcay Peker, Betil Ozhak, Aykut Ozkul, Kataline Foldes
Summary: This study investigated the mutations in the UL97 gene of CMV in patients who developed CMV infection following HCT or SOT. The results showed that clinical resistance associated with CMV UL97 mutation was detected in HCT patients, while no UL97 mutation was detected in SOT patients.
MIKROBIYOLOJI BULTENI
(2023)
Article
Immunology
Robin K. Avery, Sophie Alain, Barbara D. Alexander, Emily A. Blumberg, Roy F. Chemaly, Catherine Cordonnier, Rafael F. Duarte, Diana F. Florescu, Nassim Kamar, Deepali Kumar, Johan Maertens, Francisco M. Marty, Genovefa A. Papanicolaou, Fernanda P. Silveira, Oliver Witzke, Jingyang Wu, Aimee K. Sundberg, Martha Fournier
Summary: In this randomized comparative study, Maribavir was found to be more effective than investigator-assigned treatment for refractory cytomegalovirus infections. Maribavir also had fewer adverse effects in terms of nephrotoxicity, myelotoxicity, and treatment discontinuations.
CLINICAL INFECTIOUS DISEASES
(2022)
Article
Virology
Seungwan Chae, Hoon Seok Kim, Sung-Yeon Cho, Dukhee Nho, Raeseok Lee, Dong-Gun Lee, Myungshin Kim, Yonggoo Kim
Summary: This study aimed to identify variants associated with CMV drug resistance in HCT recipients and assess their clinical significance. The study found that 8.1% of patients had resistance variants, and 39.0% of patients had variants of uncertain significance. Patients with resistance variants had higher CMV viral load and higher risks of severe graft-versus-host disease and lower one-year survival rates.
Article
Pharmacology & Pharmacy
Jocelyne Piret, Nathalie Goyette, Guy Boivin
Summary: Letermovir (LTV) exhibits similar susceptibility against clinical HCMV isolates and recombinant viruses with similar drug susceptibility phenotypes to currently-approved DNA polymerase inhibitors or maribavir.
ANTIVIRAL RESEARCH
(2022)
Letter
Cell & Tissue Engineering
Carla de Castro Sant' Anna, Silvia Regina da Cruz Migone, Carlos Alberto Machado da Rocha, Fernando Augusto Rodrigues Mello, Aline Damasceno Seabra, Thais Brilhante Pontes, Joao Marildo Rodrigues, Salome Aparecida Soares, Viviane de Paiva Rego, Joana Paula Figueira, Ana Paula Monteiro Rodrigues, Rommel Mario Rodriguez Burbano
Summary: This study aimed to investigate mutations in the CMV genes UL97 and UL54 associated with antiviral resistance, which have become a major problem related to high mortality in kidney transplant patients. The study found mutations in CMV genes in kidney transplant patients that are associated with resistance to conventional antivirals.
CELL TRANSPLANTATION
(2023)
Article
Microbiology
Diana D. Wong, Wendy J. van Zuylen, Talia Novos, Sophie Stocker, Stephanie E. Reuter, Jane Au, Charles S. P. Foster, Richard O. Day, Andrea R. Horvath, Zoltan Endre, William D. Rawlinson
Summary: This study examined the pharmacokinetics and viral genomic data from kidney transplant recipients undergoing valganciclovir prophylaxis. Using high-throughput sequencing, ganciclovir resistance mutations were detected for the first time during subtherapeutic plasma ganciclovir, as indicated by the pharmacokinetic parameter AUC(24). The study found that current valganciclovir dosing guidelines for CMV prophylaxis are not effective in achieving therapeutic targets in a significant portion of recipients.
MICROBIOLOGY SPECTRUM
(2022)
Article
Multidisciplinary Sciences
Satoshi Tamura, Satoshi Osawa, Natsuki Ishida, Takahiro Miyazu, Shinya Tani, Mihoko Yamade, Moriya Iwaizumi, Yasushi Hamaya, Isao Kosugi, Takahisa Furuta, Ken Sugimoto
Summary: This study investigated the prevalence of CMV UL97 gene mutations in patients with colonic CMV infection associated with or without UC. The results showed that no known GCV resistance mutations were found in GCV-naive patients, regardless of the presence of UC. The D605E polymorphism may serve as a genetic marker for CMV in East Asian countries, consistent with previous reports.
SCIENTIFIC REPORTS
(2021)
Article
Biotechnology & Applied Microbiology
I. Relano-Rodriguez, M. S. Espinar-Buitrago, V. Martin-Canadilla, R. Gomez-Ramirez, J. L. Jimenez, M. A. Munoz-Fernandez
Summary: Polyanionic carbosilane dendrimers have shown potential application in inhibiting HCMV infection and enhancing the activity of current treatments, representing a low-cost approach to fight HCMV infections.
JOURNAL OF NANOBIOTECHNOLOGY
(2021)